Martin Jacko

Company: Aperture Therapeutics

Job title: Chief Executive Officer

Seminars:

Panel Discussion: To What Extent are In Vivo Models Relevant Purely in Evaluating Toxicity & Target Engagement? 11:30 am

Highlighting the need for robust toxicity and bioavailability data showcased in vivo systems Critically evaluating the ability of animal models to predict drug efficacy in treating ALS patients, and the relevance of target engagement data in vivo with different modalities of treatment (including gene therapies) Navigating regulator perspective across FDA, EMA and more to the…Read more

day: Conference Day One Track A

Identification & Targeting of Novel Protective Disease Modifiers in ALS 2:00 pm

Unpacking the role of genetic heterogeneity in ALS in drug development Identifying new genetic variants that show protection or slow down disease progression and extended survival in ALS Developing therapeutics to navigate targets in ALS Highlighting functional molecular rescue data – exploring heterogeneous studiesRead more

day: Conference Day One Track A PM